Dr. Dagogo-Jack is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
Boston, MA 02115Phone+1 617-732-5500
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2014 - 2017- Brigham and Women's HospitalResidency, Internal Medicine, 2011 - 2014
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2011
Certifications & Licensure
MA State Medical License 2015 - 2026
NH State Medical License 2021 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society, 2011
Publications & Presentations
PubMed
- Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kina...Florence K Keane, Beow Y Yeap, Melin J Khandekar, Jessica J Lin, Ibiayi Dagogo-Jack
International Journal of Radiation Oncology, Biology, Physics. 2025-03-15 - 2 citationsTreatment of Pleural Mesothelioma: ASCO Guideline Update.Hedy L Kindler, Nofisat Ismaila, Lyudmila Bazhenova, Quincy Chu, Jane E Churpek
Journal of Clinical Oncology. 2025-03-10 - Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights.Hedy L Kindler, Ibiayi Dagogo-Jack, Marc de Perrot, Michael W Drazer, Nofisat Ismaila
JCO Oncology Practice. 2025-03-07
Lectures
- Longitudinal analysis of plasma ALK mutations during treatment with next-generation ALK inhibitors.2019 ASCO Annual Meeting - 6/1/2019
- Clinicopathologic characteristics and molecular features of BRG1-deficient non-small cell lung cancer (NSCLC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Lung Cancer Research Foundation Creates Scientific Executive CommitteeJuly 11th, 2022- Join VA and the White House Today for a Cancer Cabinet Community ConversationMay 4th, 2022
- In Expected Decision, FDA Rejects Lilly's Sintilimab in NSCLCMarch 24th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
